• Oncotelic Therapeutics announced a four-gene prognostic signature in liver cancer, supporting patient selection for Sapu003 clinical trials.
• The signature's association with survival was independently validated in a Japanese hepatocellular carcinoma cohort of 203 patients.
• The study, published October 23, 2026, in Biomedicines, combined AI-guided literature analysis using PDAOAI with gene-expression and survival analyses.
• Sapu003 is an intravenous formulation of everolimus, an mTOR inhibitor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260800PRIMZONEFULLFEED9852633) on October 26, 2026, and is solely responsible for the information contained therein.